- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Wishbone for Barrier Thearpeutic's Vusion
Pharmaceutical Executive
It's not unusual for creative teams to ask actors to work up on-screen tears. But when you go from crying actors to crying babies, it makes all the difference.
CRYING BABY
Wishbone
BRAND Vusion CLIENT Barrier Therapeutics FROM LEFT: Renee Mellas, partner, general manager; Scott Sager, senior vice president, creative director; Steve Hamburg, partner, chief creative officer
It's not unusual for creative teams to ask actors to work up on-screen tears. But when you go from crying actors to crying babies, it makes all the difference. That crying baby formed the basis of the print and television campaign Wishbone created for Barrier Therapeutics' anti-fungal pediatric ointment Vusion. "It's wired into parents as an incentive to action," says Steve Hamburg, partner/chief creative officer. "These are things that get parents' attention almost genetically."
The accompanying creative keeps consistent with the esthetic of "baby-ness." "It's time for a change" was used as a pun on the double meaning of the dirty diaper and the therapy.
Hamburg says that the DTC spot was so effective that it produced a dramatic increase in prescriptions for the drug.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
